---
title: "Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294684834.md"
description: "Ocular is set to submit the NDA for AXPAXLI TM, targeting wet AMD, in Q4 2026 after a successful Type C Meeting with the U.S. FDA in May 2026."
datetime: "2026-08-03T11:03:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294684834.md)
  - [en](https://longbridge.com/en/news/294684834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294684834.md)
---

# Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular is set to submit the NDA for AXPAXLI TM, targeting wet AMD, in Q4 2026 after a successful Type C Meeting with the U.S. FDA in May 2026.

### Related Stocks

- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)

## Related News & Research

- [Ocular Therapeutix grants new SVP Beth Rada options for 85,000 shares, 28,000 RSUs under inducement plan](https://longbridge.com/en/news/295840860.md)
- [Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices](https://longbridge.com/en/news/294775792.md)
- [Readystate Asset Management LP Makes New Investment in Ocular Therapeutix, Inc. $OCUL](https://longbridge.com/en/news/294190211.md)
- [Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks](https://longbridge.com/en/news/285319328.md)
- [Ocular Therapeutix to present at ASRS annual meeting](https://longbridge.com/en/news/291404170.md)